Trial Profile
A Randomized, Double-blind, Multicenter, Parallel, Placebo-controlled Study l to Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX in Patients With Acutely Decompensated Heart Failure : Korea Bridging Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Decompensated heart failure
- Focus Registrational; Therapeutic Use
- Sponsors Yooyoung Pharmaceutical
- 07 May 2021 Status changed from not yet recruiting to recruiting.
- 07 May 2021 Planned End Date changed from 30 May 2019 to 30 Jul 2022.
- 07 May 2021 Planned primary completion date changed from 30 Apr 2019 to 30 Jan 2022.